Investigation of the cancer cell membrane proteome to find new vulnerabilities in non- small cell lung cancer

The surface proteome of non-small cell lung cancer (NSCLC) cells expresses specific pairs of proteins, which can be used as targets for delivering cytotoxic agents (e.g. antibody drug conjugates or prodrugs) or immune cells (CAR-T cells or bispecific T cell engagers) in proximity to cancer cells.

We aim to study NSCLC organoid models derived from patients and a panel of normal cells to map the membrane proteome using orthogonal methods on mass spectroscopy platforms.

Novel pairs of proteins will be validated by immunohistochemistry in tumour samples and will be leads for future drug discovery efforts.